Exploring the most advanced techniques in LC-MS analysis of drugs of abuse reveals a myriad of innovations and methodologies, incorporating key products like Supelco and Ascentis HPLC columns to enhance analytical accuracy. The optimization of these technologies allows for precise bioanalysis of diverse compound groups, including opioids and designer drugs, within biological matrices.
Purpose scope and product ecosystem for LC-MS drug analysis
Purpose and scope
This compilation guide focuses on optimizing LC-MS analysis of drugs of abuse in biological samples. It consolidates method-building considerations and application conditions using Supelco R Analytical Products to support robust qualitative and quantitative workflows. The intent is to streamline selection of columns, sample preparation, and reference materials so scientists can refine sensitivity, separation, and throughput across diverse analyte classes. All highlighted solutions are available for convenient procurement from Chemical Express to enable efficient implementation.
Product ecosystem featured
The application spotlights a modular toolkit spanning columns and sample preparation for small molecule bioanalysis. Products highlighted include Supelco R Analytical Products from Merck such as:
- Ascentis® Express Biphenyl Column
- Purospher™ STAR RP-18 endcapped
- Ascentis® Express Phenyl-Hexyl HPLC Column
- Supel™ Swift HLB 96-well SPE plates
- Ascentis® Express C18 column
- Ascentis® Express ES-Cyano column
- Astec® CHIROBIOTIC® V2
Compound groups covered
This guide compiles applications and conditions for:
- Opioids, designer drugs, synthetic hallucinogens, HCI, amphetamines, alcohol, Z-drugs
Categories included
Representative drugs of abuse classes addressed:
- Alcohols, amphetamines, barbiturates, benzodiazepines, boosters
- Cannabis or cannabinoids, cathinones, cocaine, hallucinogens
- Kratom, methaqualone, opioids, steroids, Z-compounds
Analytical imperative
These substances are controlled in most countries due to harmful intoxicant effects, requiring monitoring. Method optimization strengthens LC-MS accuracy within complex biological matrices by aligning separation selectivity, sensitivity, and speed with defined goals. The following chapter situates this analytical work within the global monitoring and regulatory landscape that drives method fitness for purpose and underscores product-enabled routes to compliance available via Chemical Express.
Global monitoring and regulatory framework
Europe overview
EMCDDA provides the EU and member states with drug status data. These outputs support laws and strategies.It collaborates with EU institutions, the Reitox network, candidate countries, and ENP countries. Regional and international organizations are also partners. Reitox compiles national monitoring results into reports such as the European Drug Report.
EU policy instruments
The EU Security Union Strategy 2020-2024 targets drug demand and supply reduction. The EU Agenda and Action Plan on Drugs 2021-2025 has the same focus. Cross cutting themes include coordination and international cooperation. Information, research, monitoring, and evaluation are also emphasized.
United States
The FDA regulates drugs of abuse tests for consumers and healthcare professionals. Reviews cover design, performance, instructions, and packaging. The FDA does not review tests for employment or insurance testing.
International organizations
Monitoring and control involve UNODC, INCB, and WHO. The Council of Europe and the World Customs Organisation are also involved. Monitoring of drugs of abuse is a coordinated international effort.
Analytical implications
Test methods must be fit for purpose to quantify drugs and endogenous substances in biological samples. They should provide qualitative and quantitative data on drugs and metabolites. Chemical Express offers product enabled routes to compliance and robustness, including:
- Supelco R Analytical Products
- Ascentis® Express Biphenyl Column
- Purospher™ STAR RP-18 endcapped
- Ascentis® Express Phenyl-Hexyl HPLC Column
- Supel™ Swift HLB 96-well SPE plates
- Ascentis® Express C18 column
- Ascentis® Express ES-Cyano column
- Astec® CHIROBIOTIC® V2
This foundation leads directly into bioanalysis concepts and current technology trends.
Bioanalysis foundations and current trends
Foundations of bioanalysis
Bioanalysis is the quantification of drugs, metabolites, and biological compounds in biological samples. It has traditionally focused on small molecules in biological fluids. Over the past 20 years, it expanded to biopharmaceuticals, including proteins and peptides. These foundations underpin confirmatory LC-MS workflows supported by Supelco R Analytical Products and column technologies used across the application examples in this series.
Analyte classes
Analytes fall into two broad categories:
- Endogenous substances: originate from organisms, tissues, or cells and include small molecule metabolites and biologically active compounds.
- Drugs: mostly synthetic, exogenous small molecules; some drugs are proteins, such as insulin.
In the application examples described, reversed phase LC-MS/MS and selective sample preparation enable quantification of both parent drugs and metabolites in complex matrices.
Absorption rules and API properties
Lipinski’s rule of five describes passive diffusion for typical orally absorbed APIs:
- Molecular weight less than 500
- LogP less than 5
- Fewer than 5 hydrogen bond donors
- Fewer than 10 hydrogen bond acceptors
These rules apply to passive diffusion; active transport via proteins is an exception. About 10 percent of marketed drugs, mainly hydrophilic chemotherapeutics, do not follow these rules.
Routes and core LC technology
Small molecule drugs are often orally administered, while biologics usually require injection. Reversed phase HPLC has been a primary pharmaceutical analysis method for APIs for over 25 years. According to the application examples, reversed phase LC-MS/MS is implemented on platforms such as Purospher™ STAR RP-18 endcapped, Ascentis® Express Phenyl-Hexyl HPLC Column, and Ascentis® Express Biphenyl Column to support rapid, reliable quantification.
Current technology trends
- LC-MS/MS is the gold standard for confirmatory drug testing.
- LC-TOF-MS is used for comprehensive drug screening.
- Alternative matrices are gaining interest: saliva, sweat, hair, and meconium; urine remains most common.
- Increasing need to characterize and identify isomeric metabolites, including chiral recognition for enantiomers.
- Miniaturization in separation and detection enhances rapid, sensitive testing.
In the application examples described, chiral recognition is enabled on Astec® CHIROBIOTIC® V2, and efficient extractions use Supel™ Swift HLB 96-well SPE plates.
Community and collaboration
Bioanalytical organizations such as AAPS, BSAT or APA, CVG, EIP, EUFEPS, FABIAN, GBC and JBF advance best practices and harmonization. Their collective efforts align with monitoring imperatives described previously and support assay robustness, from screening to confirmation.
From concepts to practice
These principles translate into product-enabled workflows that address drugs of abuse testing needs. In the application examples described, balanced selectivity and speed are demonstrated on Ascentis® Express C18 column and Ascentis® Express ES-Cyano column. Chemical Express provides access to the featured Supelco R Analytical Products portfolio to support your next study. The next chapter details a practical method development strategy and fitness for purpose.
Method development strategy for drugs of abuse
1. Reference-informed technique selection
Selecting an optimal LC-MS approach for drugs of abuse is eased by high quality references. Use official test methods from organizations and databases, peer-reviewed studies, and comparable application notes as practical reference points. This evidence base helps narrow choices for chromatography, ionization, and sample preparation, and provides realistic expectations for selectivity and sensitivity. Chemical Express can supply the referenced platforms so teams can replicate or adapt proven conditions without introducing unnecessary variables during early development.
2. Define goals and fit for purpose
Set clear analytical goals before lab work. Define resolution, analysis time, and sensitivity targets. Balance selectivity, speed, and efficiency to achieve a robust, cost-efficient assay with an acceptable price per analysis. This alignment guides column chemistry, mobile phases, and cleanup choices, and supports method verification, validation, and routine implementation. Early alignment reduces rework and accelerates transfer to routine use.
3. Avoid common development errors
- Unclear goals
- Poor chemistry knowledge
- Trial and error
- Wrong instrument setup
Information to gather before experiments
- Quantitative or qualitative analysis
- Required accuracy and precision
- Availability of analytical standards and reference materials
- Number of analytes to detect
- Need to identify or resolve all sample components
- Number and type of sample matrices
- Daily sample volume and annual throughput
Key physicochemical and matrix parameters
- Sample nature: urine, plasma, serum, whole blood
- Number of analytes
- Chemical structure and functionality
- Molecular weight and pKa values
- Log P or Log D
- Expected concentration ranges
- Sample matrix and solubility
- Solubility, analyte differentiation, and matrix effects
Bridging strategy to execution
Once goals and inputs are defined, select separation and cleanup tools demonstrated in application examples. Options include columns such as Ascentis® Express Biphenyl Column, Purospher™ STAR RP-18 endcapped, Ascentis® Express Phenyl-Hexyl HPLC Column, Ascentis® Express C18 column, Ascentis® Express ES-Cyano column, and chiral Astec® CHIROBIOTIC® V2, plus SPE formats like Supel™ Swift HLB 96-well SPE plates. Chemical Express distributes these Supelco R Analytical Products. The next chapter details the end to end analytical workflow.
End to end analytical workflow
Build a fit for purpose, LC based workflow for drugs of abuse testing with a clear, staged path from sample to report. Chemical Express supplies integrated solutions from Supelco R Analytical Products, enabling consistent execution from sampling through validation. The sequence below aligns with the defined analytical workflow and supports LC MS, LC MS MS, and LC TOF MS applications for opioids, designer drugs, alcohol markers, amphetamines, and Z drugs.
- Sampling and preservation: Follow defined procedures for collection, storage, and preservation to maintain analyte integrity across matrices.
- Fortification if applicable: Spike calibration and quality materials as planned to support quantitation and identification.
- Sample preparation: Select from LLE, protein precipitation, SPE, or SPME. SPE offers better recoveries, less solvent use, smaller sample volumes, and higher throughput. It is adaptable to fully automated systems.
- Sample adjustments if applicable: Apply adjustments only as specified in the method plan before analysis.
- Addition of internal standards: Add at the start. Align with calibration, dilution, and SOPs to control recovery and matrix effects.
- Chemical analysis: Use LC MS MS for confirmatory testing and LC TOF MS for comprehensive screening. Application examples include separations on Ascentis® Express Biphenyl Column, Purospher™ STAR RP-18 endcapped, Ascentis® Express Phenyl-Hexyl HPLC Column, Ascentis® Express C18 column, Ascentis® Express ES-Cyano column, and chiral recognition on Astec® CHIROBIOTIC® V2.
- Data analysis: Process qualitative and quantitative outputs for drugs and metabolites as defined by the method goals.
- Post analytical activities: Perform validation and method transfer protocols, including linearity, repeatability, reproducibility, and recovery.
- Internal standard strategy and recovery: Analyte loss during pre treatment is inevitable. Recovery must be determined for method validity.
- Add internal standards at the start. They should have similar protein binding strength and physicochemical properties to mimic analyte behavior.
- Isotope dilution via LC MS or LC MS MS is preferred for recovery determination. Deuterated analytes are ideal internal standards due to identical chemistry and distinguishable mass.
- Maintain calibration, dilution, and SOP discipline throughout to ensure comparability.
This workflow sets up the next step. The following chapter defines biological matrices and preservation needs, including plasma, serum, tissue, and urine handling, to ensure matrix appropriate sampling and storage before sample preparation and SPE optimization.
Biological matrices properties and preservation
Understanding biological matrices is fundamental for LC-MS analysis of drugs of abuse. Matrix properties influence preservation, sample preparation, and downstream performance with solutions such as Supelco R Analytical Products. The following definitions and preservation notes support reliable quantitation and screening across workflows.
- Plasma: The liquid portion of blood obtained after centrifugation when an anticoagulant is added to prevent clotting. Anticoagulants bind calcium ions and include:
- Sodium citrate
- EDTA
- Potassium oxalate
- Heparin
- Serum: The liquid remaining after clot removal. It lacks clotting proteins such as fibrinogen and differs from plasma by the absence of these proteins.
- Tissue: A group or layer of similar cells that perform specific functions.
- Urine: A kidney-filtered excrement fluid containing various metabolic products. It is commonly used in drug abuse testing.
- Storage and preservation:
- Plasma, serum, and tissue samples are stable and can be stored in plastic containers at down to −20 °C without special precautions.
- Urine requires preservatives to prevent bacterial degradation.
These characteristics inform the next steps in method development, including enrichment, cleanup, and ionization control. The following chapter will compare sample preparation strategies and detail SPE optimization, including high-throughput options such as Supel™ Swift HLB 96-well SPE plates. Chemical Express supports alignment of matrix handling with downstream workflows built on Supelco R Analytical Products, Ascentis® Express C18 column, and related solutions.
Sample preparation options and SPE optimization
Effective LC MS workflows begin with fit for purpose sample preparation. Using Supelco R Analytical Products, laboratories can align preparation strategy with matrix properties, analyte chemistry, and throughput goals. The approaches below support downstream separations on columns such as Ascentis® Express Phenyl-Hexyl HPLC Column, Ascentis® Express C18 column, Ascentis® Express ES-Cyano column, and chiral workflows on Astec® CHIROBIOTIC® V2, enabling robust qualitative and quantitative drug analysis.
Liquid liquid extraction LLE
- Previously predominant for small molecules; now less favored due to efficiency of newer methods.
- Solvent choice depends on analyte polarity and protein binding; full requirements are rarely met, leading to low extraction efficiencies.
- Non selective co extraction of lipids causes downstream interferences; lipid removal is only partial.
- Many organic solvents are incompatible with plastics, requiring glass vessels.
- Some analytes bind to glass surfaces; use silanized glassware or plastics to limit contamination.
- Requires large volumes of toxic or flammable solvents, complicating handling and disposal.
- Despite drawbacks, LLE remains a common purification method.
Protein precipitation protein crash
- Uses solvents, acids, bases, or salts to precipitate proteins; removes up to 95 percent of proteins.
- Fast and simple, but lipids and minerals remain and may cause column issues and ionization suppression or enhancement.
- Protein solubility reflects hydrophilic hydrophobic amino acid distribution and ionic interactions.
- Adding miscible solvents such as methanol lowers the dielectric constant of water, reduces solvation, and promotes precipitation.
Solid phase extraction SPE
- Offers better recoveries, less solvent use, smaller sample volumes, and higher throughput compared to LLE.
- User friendly and readily adapted to fully automated sample preparation systems.
- Wide sorbent chemistries support diverse interaction modes: reversed phase, normal phase, ion exchange, adsorption.
- New sorbents and formats such as discs, syringes, and membranes address selective, efficient work up needs.
SPE method implementation checklist
- Assess sample characteristics: pKa, molecular weight, polarity, matrix, and interferences.
- Select sorbent type: reversed phase, normal phase, ion exchange, or adsorption.
- Choose solvents guided by elution profiles.
- Develop the procedure: condition the solid phase, apply sample, perform pretreatment to remove loosely bound matrix, elute analytes while minimizing matrix co elution.
- After establishing the procedure, test breakthrough volume to define maximum extractable amount by volume and weight.
- Validate linearity, repeatability, reproducibility, and recovery.
For high throughput urine workflows, Supel™ Swift HLB 96-well SPE plates provide a hydrophilic lipophilic polymer phase for broad compound extraction from complex aqueous matrices. In the application example described, they were applied to urine sample preparation for pain management drugs without a post extraction concentration step, with minimal matrix effects after cleanup. The next chapter details the complete hydrolysis, SPE, and LC MS or MS MS workflow and performance, setting the stage for targeted analyses on Ascentis® Express Biphenyl Column.
High throughput opioid cleanup with Supel Swift HLB plates
High-throughput justification
• The Supel™ Swift HLB 96-well SPE plates format is suited for high-throughput clinical labs.
• SPE is the preferred cleanup method before LC-MS injection in this workflow.
• Drug metabolites such as morphine glucuronide require β-glucuronidase hydrolysis before LC-MS to analyze the free drug form.
• SPE cleanup was applied to urine mimic samples.
Sample setup and spiking
• Matrix: Sigmatrix urine diluent spiked with Pain Management Multi-Component Opiate Mixture-13 at 100 ng/mL for 12 compounds and fentanyl at 10 ng/mL.
• Internal standards added at 10 ng/mL each: oxycodone D-3, oxymorphone D-3, hydrocodone D-3, cis-Tramadol-13C,D3, meperidine D-4, and plus minus Methadone-D9.
Enzymatic hydrolysis
• Prepare β-glucuronidase solution at 10 kU per 9 in 0.1 M phosphate buffer, pH 6.
• Bulk sample mixing ratio: 3 to 1 to 1 of Sigmatrix urine diluent to β-glucuronidase to phosphate buffer.
• Digest for 2 hours at 60 °C with 200 rpm mixing optimized for limpet β-glucuronidase.
• Cool and adjust pH to 9 with ammonium hydroxide.
SPE cleanup on Supel™ Swift HLB 96-well SPE plates
• Sorbent: 30 mg HLB per well.
• Process hydrolyzed samples on the 96-well plate.
• After processing, dilute 75 µL cleaned sample with 175 µL LC-MS grade water to a final 30 percent organic content.
• No post-extraction concentration step was needed in the application example.
LC-MS system and separation
• LC: Agilent 1290; MS: Sciex 3200 QTrap.
• Column: Ascentis® Express Phenyl-Hexyl HPLC Column, 10 cm x 2.1 mm, 2.7 µm (Cat. 53336-U).
• Mobile phases: A water plus 0.1 percent formic acid; B acetonitrile plus 0.1 percent formic acid.
• Gradient: 10 percent to 45 percent B in 3 min, to 100 percent B in 2 min, hold 2.4 min.
• Flow rate: 0.300 mL/min; column temperature: 30 °C.
• Detection: MS, ESI positive mode, scheduled MRM.
Quantification and calibration
• Quantification by a 5-point external calibration curve.
• Standards prepared daily from methanol stock in glass vials.
• Final standards: 70 to 30 methanol to water with 10 ng per mL internal standards.
Performance results
According to the experiment data:
• Average recoveries (RSD): Morphine 88 percent (5.4), Oxymorphone 94 percent (4.1), Hydromorphone 94 percent (5.5), Naloxone 74 percent (6.9), Codeine 105 percent (7.2), Naltrexone 75 percent (6.2), Oxycodone 92 percent (6.7), Hydrocodone 90 percent (4.6), Tramadol 89 percent (2.0), Meperidine 93 percent (3.3), Fentanyl 73 percent (6.1), Buprenorphine 44 percent (5.8), Methadone 90 percent (2.7).
• 12 of 13 analytes had average recoveries 73 to 105 percent, n equals 96.
Reproducibility and matrix effects
• Overall recovery excluding buprenorphine: 88 percent, RSD 10.8 percent.
• Reproducibility RSDs less than or equal to 7.2 percent across the 96-well plate.
• Matrix effects were minimal, within plus or minus 10 percent ionization impact after SPE cleanup.
Materials checklist
• Supel™ Swift HLB 96-well SPE plates, 30 mg/well (Cat. 57494-U).
• Ascentis® Express Phenyl-Hexyl HPLC Column, 2.7 µm, 100 x 2.1 mm (Cat. 53336-U).
• Acetonitrile and Methanol LiChrosolv gradient grade; LC-MS grade water LiChrosolv.
• Seal Plate Film; PlatePrep 96-well Vacuum Manifold starter kit (575650-U).
• Sigmatrix Urine Diluent (SAE0074); Pain Management Multi-Component Opiate Mixture-13, P-071-1ML.
• Deuterated standards: Hydrocodone-D3, Meperidine-D4, Methadone-D9, Oxycodone-D3, Oxymorphone-D3, cis-Tramadol-13C,D3.
Chromatographic context
• In the application example described, chromatography for 13 analytes used the Ascentis® Express Phenyl-Hexyl HPLC Column with MS detection in ESI positive mode and scheduled MRM.
• SPE cleanup was applied to urine mimic samples prior to LC-MS.
Availability and next steps
• All products are available through Chemical Express.
• Next, we present targeted fentanyl and analog analysis on the Ascentis® Express Biphenyl Column.
Targeted fentanyl and analog analysis on Ascentis Express Biphenyl
Rationale for using a biphenyl stationary phase
Fentanyl and its analogs contain delocalized pi electrons in benzene rings or amide groups. Biphenyl ligands in the stationary phase also contain pi electrons. This enables pi pi stacking interactions between analytes and the stationary phase. The planar biphenyl structure further discriminates structurally similar analytes. In the application examples described, this interaction enhances resolution for targeted LC-MS and LC-MS/MS assays.
Targeted LC-MS after SPME LC fiber extraction on Ascentis® Express Biphenyl Column
- Column: Ascentis® Express Biphenyl Column, 5 cm × 2.1 mm I.D., 2.7 μm, 64057-U
- Mobile phase: A 0.1% formic acid in water; B 0.1% formic acid in methanol
- Gradient: 40% to 90% B over 1.5 min; hold 90% B for 1 min
- Flow rate: 0.6 mL/min; Column temperature: 30 °C
- Pressure: about 4206 psi (290 bar); Injection: 0.5 μL
- Detector: MS, ESI positive, SIM at m/z 233, 323, 337, 387
- Sample: Synthetic urine spiked with norfentanyl 800 ng/mL, acetyl fentanyl 400 ng/mL, fentanyl 800 ng/mL, sufentanil 800 ng/mL; diluted 1:9 with water
SPME LC fiber workflow and BioSPME advantages
- Condition fiber: 50:50 methanol:water, 1 mL, 30 min, 800 rpm
- Rinse: water, 1 mL, 10 s, 800 rpm
- Extract: urine, 1 mL, 30 min, 800 rpm
- Rinse: water, 1 mL, 10 s, 800 rpm
- Desorb: 90:10 methanol:water with 0.1% ammonium hydroxide, 200 μL, 30 min, 800 rpm
- SPME extracts only the free drug portion; calibration curves in synthetic urine determine recovery
- BioSPME fibers feature a non-swelling, biocompatible coating to minimize protein and phospholipid binding
- BioSPME enables direct extraction from complex matrices, reduces matrix effects, and eliminates steps used in SPE and dilute and shoot
LC-MS or MS-MS of multiple fentanyl analogs on Ascentis® Express Biphenyl Column
- Column: Ascentis® Express Biphenyl Column, 5 cm × 2.1 mm, 2.7 μm
- Gradient: 40% B to 50% B in 2 min; to 80% B in 1 min; hold 1 min; return to 40% B in 0.1 min; hold 1.4 min
- Flow rate: 0.6 mL/min; Column temperature: 50 °C
- Injection: 4 μL; Detection: MS or MS-MS
According to the experiment data, the column provided good resolution of nine fentanyl analogs for accurate quantitation. The biphenyl selectivity and planar interaction supported separation of structurally similar compounds.
Materials for targeted fentanyl workflows
- Ascentis® Express Biphenyl Column, 2.7 μm, 5 cm × 2.1 mm (64057-U)
- LC-MS grade methanol and water
- Formic acid 98–100%
- Certified reference materials: acetyl fentanyl, fentanyl, fentanyl related compounds, sufentanil citrate
- Ultrapure water from a Milli-Q IQ 7 system
Complementary UHPLC MRM configuration
- Column: Titan C18, 5 cm × 2.1 mm I.D., 1.9 μm, 577122-U
- Mobile phase: 0.1% formic acid in water (A) and acetonitrile (B)
- Gradient: 15% B, 0.3 min; 30% B, 5.5 min; 95% B, 7.0 min
- Flow rate: 0.4 mL/min; Column temperature: 40 °C
- Instrument: Agilent 1290 UHPLC with 6495 Triple Quad
- Mode: Positive ion MRM; Injection: 1.0 μL
- Sample: 1.0 ng/mL in 90:10 methanol:water
This complementary setup was reported alongside the biphenyl-based methods to support targeted quantitation.
Next steps toward buprenorphine quantitation
The next chapter details LC-MS or MS-MS quantitation of buprenorphine and norbuprenorphine on Purospher™ STAR RP-18 endcapped. Products featured in this section are available through Chemical Express to support targeted opioid analysis using brochure-documented workflows and materials.
Quantitation of buprenorphine and norbuprenorphine on Purospher STAR RP-18
Buprenorphine pharmacology and metabolism
Buprenorphine is a synthetic opioid used for pain and opioid addiction treatment. It is metabolized to norbuprenorphine via CYP3A4 in the liver. Both compounds conjugate to glucuronides. Maximum plasma concentration occurs 30 minutes to 3 hours post administration.
Analytical approach and quantitation ranges
In the application example described, reversed phase LC-MS or MS-MS with isotopically labelled internal standards supports reliable quantitation in urine.
- Buprenorphine linear range: 1 to 100 ng/mL
- Norbuprenorphine linear range: 5 to 1000 ng/mL
Chromatographic conditions on Purospher™ STAR RP-18 endcapped
- Column: Purospher™ STAR RP-18 endcapped, 2 µm, 5 cm × 2.1 mm I.D.
- Mobile phase A: 0.1% formic acid in ultrapure water
- Mobile phase B: 0.1% formic acid in acetonitrile
- Gradient profile:
- 0 min: 90% A, 10% B
- 0.25 min: 90% A, 10% B
- 10 min: 90% A
- Flow rate: 0.7 mL/min
- Column temperature: 40 °C
- Pressure: about 230 bar, 3312 psi at gradient start
- Injection volume: 10 µL
- Diluent: mobile
Materials and reagents
- Purospher™ STAR RP-18 endcapped, Hibar HR 50 × 2.1 mm I.D. (Cat. 150646)
- Acetonitrile hypergrade for LC-MS LiChrosolv (Cat. 100029)
- LC-MS grade water LiChrosolv (Cat. 115333)
- Ultrapure water, Milli-Q® IQ 7 system (Cat. ZIQ7005TOC)
- Formic acid 98 to 100% for LC-MS LiChropur (Cat. 533002)
From targeted analytes to broader opioid panels
This targeted workflow complements rapid LC-MS of multiple opioids on the Ascentis® Express Phenyl-Hexyl HPLC Column, as detailed in the following chapter. Chemical Express can supply the listed columns and LC-MS reagents alongside Supelco® R Analytical Products to streamline implementation across opioid methods.
Rapid LC-MS of multiple opioids with Ascentis Express Phenyl-Hexyl
Rapid LC-MS panel on phenyl-hexyl
In the application example described, LC-MS was used for rapid, efficient analysis of 13 pain management opioids on the Ascentis® Express Phenyl-Hexyl HPLC Column. Supelco certified reference materials (CRMs) ensure reliable identification and quantification. This targeted setup complements the reversed phase workflow introduced for buprenorphine and norbuprenorphine and prepares the transition to the tramadol method in the next chapter.
Chromatographic conditions
- Column: Ascentis® Express Phenyl-Hexyl HPLC Column, 10 cm × 2.1 mm, 2.7 µm, Cat. 53336-U
- Mobile phase: A = water + 0.1% formic acid; B = methanol + 0.1% formic acid
- Gradient: 10% to 45% B in 3 min; to 100% B in 2 min; hold 2.4 min
- Flow: 0.3 mL/min; Temp: 30 °C
- Pressure: approximately 6940 psi (478 bar)
- Injection: 2 µL
- Detector: MS, ESI positive mode, Selected Ion Recording (SIR)
Sample and standards
- Sample: Pain Management Multi-Component Opiate Mixture-13, P-071
- Preparation: Diluted to 30–300 ng/mL in 99:1 water:methanol
Materials
- Columns: Ascentis® Express Phenyl-Hexyl HPLC Column (Cat. 53336-U); Purospher™ STAR RP-18 endcapped, Hibar HR 50 × 2.1 mm, 2 µm (Cat. 150646)
- Solvents: Acetonitrile hypergrade LC-MS LiChrosolv (Cat. 100029); Methanol hypergrade LC-MS LiChrosolv (Cat. 106035); Methanol gradient grade for LC (Cat. 106007); Ethanol gradient grade LiChrosolv (Cat. 111727); Water LC-MS grade LiChrosolv (Cat. 115333); Ultrapure water Milli-Q IQ 7 (Cat. ZIQ7005TOC)
- Additives: Formic acid 98–100% LC-MS LiChropur (Cat. 533002)
This rapid, targeted phenyl-hexyl method aligns with the upcoming UHPLC-MS or MS determination of tramadol and N-desmethyl-tramadol on the Purospher™ STAR RP-18 endcapped platform, supporting consistent LC-MS workflows across opioid assays. Chemical Express can supply the columns, solvents, and CRMs to implement both panels.
UHPLC MS MS determination of tramadol in urine
Pharmacology context
Tramadol is a weak μ-opioid receptor agonist and a serotonin or noradrenalin re-uptake inhibitor. It is used for pain, restless leg syndrome, and fibromyalgia. It is structurally similar to codeine with lower dependence risk. Tramadol is extensively metabolized, with 24 metabolites identified. Chemical Express supports this workflow with proven LC-MS consumables for reliable analysis.
Analytical setup
- Technique: Reversed phase LC-MS or MS-MS with isotope-labelled internal standards.
- Matrix: Human urine analyzed with standards and controls.
- Calibration: Linear detection range 25–1500 ng/mL.
- Analytes: Tramadol and N-desmethyl-tramadol.
Chromatographic conditions
- Column: Purospher™ STAR RP-18 endcapped, 2 µm, 50 × 2.1 mm I.D.
- Mobile phase A: 0.1% formic acid in ultrapure water.
- Mobile phase B: 0.1% formic acid in acetonitrile.
- Flow: Gradient 0.4–0.5 mL/min; Temperature: 40 °C.
- Pressure: About 170 bar at gradient start.
- Injection: 5 µL; Diluent: Mobile phase A:B (50:50).
- Detection: LC-MS or MS-MS, ESI, MRM m/z 264/58 (tramadol), m/z 254/44 (N-desmethyl-tramadol).
Chromatographic data
According to the experiment data, the void volume retention time was 0.2 min. Tramadol eluted at 2.07 min. N-desmethyl-tramadol eluted at 2.09 min. These data reflect the application example described for urine analysis on Purospher™ STAR RP-18 endcapped.
Materials
- Purospher™ STAR RP-18 endcapped, Cat. 150646.
- Acetonitrile hypergrade for LC-MS LiChrosolv, Cat. 100029.
- LC-MS grade water LiChrosolv, Cat. 115333.
Chemical Express provides these UHPLC-MS supplies to streamline quantitative workflows.
Building on the targeted opioid work with the Ascentis® Express Phenyl-Hexyl HPLC Column, this tramadol method demonstrates robust UHPLC-MS operation in urine. The next chapter advances to designer drugs and synthetic hallucinogens, featuring SPE with Supel™ Swift HLB 96-well SPE plates and separations on the Ascentis® Express C18 column and HILIC formats for NBOMe and bath salts.
Screening of designer drugs NBOMe and bath salts
Overview
Designer drugs are structural or functional analogs of controlled substances that mimic pharmacological effects while avoiding legal classification and detection in standard tests. They include new psychoactive substances and analogs of performance-enhancing drugs such as designer steroids. Safety and efficacy are not thoroughly evaluated and may lead to unexpected side effects. NBOMe drugs are highly potent synthetic hallucinogens derived from 2C phenethylamines. Psychoactive bath salts are recreational designer drugs that often contain cathinones such as MDPV, methylone, or mephedrone. Their chemical composition varies and they resemble Epsom salts physically but not chemically.
NBOMe UHPLC-MS workflow after SPE
In the application example described, extraction from human urine and rapid analysis were implemented with dedicated LC-MS solvents and certified reference materials for quality.
- Column: Ascentis® Express C18 column, 10 cm × 3 mm I.D., 2 µm, 50819-U
- Column temperature: 50 °C
- Mobile phase: 20 mM ammonium acetate pH 4 (A) and acetonitrile (B), 60:40
- Flow rate: 0.8 mL/min
- Pressure: about 7700 psi (531 bar)
- Injection: 1 µL
- Detector: UV at 280 nm
- Sample: human urine spiked at 100 ng/mL per compound
- SPE: Supel™ Swift HLB 96-well SPE plates, 30 mg/well (57494-U)
- SPE steps: condition 1 mL methanol then 1 mL water; load 1 mL sample; wash 1 mL water then 1 mL water:methanol 75:25; evaporate eluate and reconstitute in 1 mL water:acetonitrile 50:50
Bath salts HILIC screening, configuration 1
According to the experiment data, LC-MS on a HILIC phase supported broad cathinone coverage.
- Column: Ascentis® Express HILIC, 10 cm × 2.1 mm I.D., 2.7 µm (53939-U)
- Mobile phase: 5 mM ammonium formate in acetonitrile (A) and water (B), premixed 98:2 A:B
- Flow rate: 0.6 mL/min
- Column temperature: 35 °C
- Pressure: about 267 psi (18.4 bar)
- Injection: 2 µL
- Detector: MS, ESI positive TOF, Summed Ion Chromatogram
- Sample concentration: 500 ng/mL in acetonitrile
Bath salts HILIC, alternative configuration and SPE protocol
- Column: Ascentis® Express HILIC, 10 cm × 2.1 mm I.D., 2.7 µm (53939-U)
- Mobile phase: 5 mM ammonium formate in acetonitrile (A) and water (B), premixed 98:2 A:B
- Flow rate: 0.6 mL/min
- Column temperature: 35 °C
- Pressure: 1842 psi (127 bar)
- Injection: 1 µL
- Detector: MS, ESI positive TIC, m/z 100–1000
- Samples: 200 µg/L each analyte in acetonitrile; urine spiked at 100 ng/mL and acidified with 0.1% formic acid for full ionization
- SPE sorbent: Discovery® DSC-MCAX, 100 mg/1 mL (52782-U)
- Condition: 1 mL 1% formic acid in acetonitrile, then 1 mL water
- Load: 1 mL spiked water blank or urine
- Wash: 1 mL water; 1 mL 1% formic acid in acetonitrile; 1 mL water
- Elute: 2 mL 10% ammonium hydroxide in acetonitrile
- Post-elution: vortex, evaporate, reconstitute in 100 µL water:methanol
Materials checklist
- Acetonitrile hypergrade LC-MS LiChrosolv® (100029)
- Methanol hypergrade LC-MS LiChrosolv® (106035)
- Ethanol gradient grade LiChrosolv® (111727)
- Water for chromatography LC-MS grade LiChrosolv® (115333)
- Ultrapure water from Milli-Q® IQ 7 (ZIQ7005TOC)
- Acetic acid 100% LC-MS LiChropur™ (533001)
- Ammonium acetate for MS LiChropur™ (73594)
- Ammonium formate eluent additive LC-MS LiChropur™ (70221)
- Potassium dihydrogen phosphate anhydrous HPLC LiChropur™ (533002)
- Triethylammonium acetate buffer for HPLC, 0.98–1.02 M
Building on opioid testing, these designer drug screens demonstrate streamlined SPE and LC-MS options that Chemical Express can supply alongside standards and high-purity reagents. The next chapter advances to chiral recognition for amphetamine-class analytes using Astec® CHIROBIOTIC® V2 to resolve enantiomers.
Chiral resolution of amphetamine and methamphetamine enantiomers
Why chiral recognition matters
Chiral recognition of isomeric drug metabolites is increasingly important. It supports LC-MS workflows that characterize and identify enantiomers. In the application example described, LC-MS chiral separation of amphetamine class enantiomers enabled discrimination between legal and illicit drug sources. Chemical Express supplies the solutions highlighted here to streamline these analyses.
Astec CHIROBIOTIC V2 LC-MS method for amphetamine enantiomers after SPE
Astec® CHIROBIOTIC® V2 enables direct LC-MS separation following mixed-mode SPE.
- Column: 15 cm x 4.6 mm I.D., 5 µm, 15023AST
- Mobile phase: methanol:water:acetic acid:ammonium hydroxide = 95:5:0.1:0.02
- Flow: 1.0 mL/min; temperature: 20 °C; injection: 2 µL
- Detector: MS, ESI positive, SIR at m/z 150.1
- Sample: 1 mL synthetic urine, 50 ng/mL each enantiomer
- SPE: Discovery DSC-MCAX 100 mg/1 mL
- Condition: 1 mL 1% formic acid in acetonitrile, then 1 mL water
- Load: 1 mL spiked urine
- Wash: 2 mL water; 1 mL 5 mM ammonium phosphate dibasic in 50% methanol; 1 mL 25% methanol in water
- Elute: 1 mL 10% w/v ammonium hydroxide in acetonitrile
- Evaporate under nitrogen at 40 °C; reconstitute in mobile phase
Alternative LC-MS application for methamphetamine enantiomers
The same Astec® CHIROBIOTIC® V2 conditions target methamphetamine enantiomers after SPE.
- Sample: 1.0 mL synthetic urine spiked with 25 ng/mL methamphetamine
- Acidify to pH 3–4 with formic acid prior to SPE
- SPE: Discovery DSC-MCAX 100 mg/1 mL
- Condition: 1 mL 1% formic acid in acetonitrile, then 1 mL water
- Wash: 2 mL water, then 1 mL 25% methanol
- Elute: 1 mL 10% ammonium hydroxide
LLE variant for methamphetamine enantiomers
A liquid-liquid extraction option can be used prior to LC-MS on Astec® CHIROBIOTIC® V2.
- Sample: 125 µL urine spiked with 125 ng/mL each enantiomer
- Add 1 mL diethyl ether; vortex 30 min
- Centrifuge 10,000 rpm for 10 min
- Remove 500 µL upper organic layer
- Evaporate under nitrogen at 55 °C
- Reconstitute in 500 µL mobile phase
- Filter through 0.22 µm PVDF membrane, Z227498
Comparative SPE performance for amphetamines
According to the experiment data, HPLC on Discovery HS F5 after DSC-MCAX showed ~9 mAU background, while standard C18 was about 20 times higher. Absolute recovery on DSC-MCAX was 100.3% for amphetamine and 101.7% for methylamphetamine, versus 48% and 79% on standard C18. These results illustrate matrix cleanup benefits for downstream chiral LC-MS.
- HPLC column: Discovery HS F5, 15 cm x 4.6 mm, 5 µm, 567516-U
- Mobile phase: 10 mM ammonium acetate pH 4.5 (A) and methanol (B), 35:65
- Flow: 2 mL/min; temperature: 40 °C; injection: 10 µL
- Detector: UV at 210 nm
- DSC-MCAX conditioning: 1 mL methanol; 1 mL 50 mM ammonium acetate pH 6.0
- DSC-MCAX wash: 1 mL 50 mM ammonium acetate pH 6.0; 1 mL 1 M acetic acid; 1 mL methanol
- DSC-MCAX elution: 1 mL 5% ammonium hydroxide in methanol
- C18 conditioning: 1 mL methanol; 1 mL DI water
- C18 wash: 1 mL DI water; 1 mL 20% methanol
- C18 elution: 1 mL methanol
Alcohol biomarkers EtG EtS and PEth
EtG and EtS overview and interpretation
Ethyl glucuronide EtG is a metabolite formed by glucuronidation after ethanol exposure. It is a biomarker for recent consumption, detectable at very low levels. EtG can yield false positives from non-beverage or incidental alcohol exposure. EtG confirms alcohol intake in post-mortem cases, but a negative EtG may be false if death occurs soon after drinking. EtG stability is compromised by bacterial degradation. Ethylsulfate EtS is a complementary metabolite resistant to bacterial degradation. Combined EtG and EtS indicate recent consumption. Phosphatidylethanols PEth are alternative markers formed by phospholipase D only in ethanol presence. EtG and EtS excretion profiles are documented.
HILIC strategy for EtG and EtS
EtG and EtS are polar and are poorly retained on C18 with early elution and matrix interference. HILIC on Ascentis® Express OH5 improves retention and quantification. Deuterated internal standards are essential for accurate quantification. External calibration causes sulfate overestimation.
- Ascentis® Express OH5 conditions: 10 cm × 2.1 mm, 2.7 μm, Cat. 53757-U
- Mobile phase A: 5 mM ammonium formate + 0.1% formic acid in 95:5 acetonitrile:water
- Mobile phase B: 5 mM ammonium formate + 0.1% formic acid in 80:20 acetonitrile:water
- Gradient: 0 to 100% B in 1 min; hold 4 min; return to 0% B; hold 5 min
- Flow: 0.4 mL/min; Column: 30 °C
SeQuant ZIC-HILIC LC-ESI ion trap-MS method for EtG and EtS
- Column: SeQuant ZIC-HILIC, 3.5 μm, 150 × 2.1 mm, Cat. 150448; Guard Cat. 150434
- Mobile phase A: acetonitrile; B: 5 mM ammonium acetate pH 6.8
- Gradient and flows:
- 0–3 min: 90% A/10% B at 0.2 mL/min
- 3.01–4 min: to 70% A/30% B at 0.4 mL/min
- 4–7 min: 70% A/30% B at 0.2 mL/min
- 7–12 min: 50% A/50% B at 0.2 mL/min
- 12.01–20 min: 90% A/10% B at 0.2 mL/min
- Column: 25 °C; Autosampler: 4 °C; Injection: 5 μL; Diluent: mobile phase
- Detection: LC-ESI ion trap-MS/MS with specified precursor and product ions
- Sample preparation:
- Add pentadeuterated internal standards to 0.1 mL urine
- Add 200 μL acetonitrile, centrifuge at 10,000 rpm
- Evaporate supernatant, reconstitute with 100 μL initial mobile phase
- Chromatographic data:
- Void time: 1.3 min
- EtS: 1.7 min, m/z 125.5 → 97.5
- EtG: 2.7 min, m/z 221.2 → 85.3
PEth on UHPLC with Ascentis® Express C18 column
- Column: Ascentis® Express C18 column, 5 cm × 2.1 mm, 2.0 μm, Cat. 50811-U
- Mobile phases: A 5 mM ammonium formate in water; B methanol; C acetonitrile
- Mixture: A:B:C at 5:47.5:47.5
- Flow: 0.5 mL/min; Column: 50 °C; Pressure: about 2760 psi (190 bar)
- Sample: 500 ng/mL in 50:50 water:acetonitrile; Injection: 2 μL
- Detection: MS, ESI negative, combined SIR at m/z 699.7 and 701.7
- Materials:
- Acetonitrile and methanol, gradient grade
- LC-MS grade water; Milli-Q IQ 7 ultrapure water
- Ammonium formate ≥99.0%, Cat. 70221
- CRMs for EtG: E-016 and E-015
These alcohol biomarker workflows complement the next case study on Z-drugs. The following chapter details UHPLC-MS analysis of zopiclone and metabolites on the Ascentis® Express ES-Cyano column. All featured products are available through Chemical Express.
Z-drugs case study using Ascentis Express ES-Cyano
Z‑drugs are psychoactive, benzodiazepine‑like compounds used to treat sleep disorders. Documented side effects include pronounced amnesia and rare hallucinations at high doses. Clinical trial data show that zolpidem, zaleplon, and eszopiclone double depression risk versus placebo. Z‑drugs are also linked to increased mortality risk. Given the abuse potential of this class, rapid urine analysis is important to support monitoring strategies. In the application example described, UHPLC‑MS on the Ascentis® Express ES‑Cyano column is used to quantify zopiclone and its metabolites with targeted MRM detection.
Chromatographic and MS conditions on Ascentis® Express ES‑Cyano column
- Column: 10 cm × 3.0 mm I.D., 2.0 µm, Cat. 51732‑U
- Mobile phase: 10 mM ammonium formate pH 3.0 with formic acid (A) and acetonitrile (B), 70:30 (A:B)
- Flow rate: 0.4 mL/min
- Column temperature: 25 °C
- Pressure: about 5300 psi (365 bar)
- Injection volume: 10 µL
- Detector: MS, MRM mode, transitions m/z 375/245, 389/245, 405/245
Sample preparation workflow
- Spike: 100 µL urine with zopiclone and metabolites at 10 ng/mL
- Internal standards: add 100 µL deuterated internal standards at 100 ng/mL in acetonitrile
- Dilute: add 800 µL water
- Centrifuge: 3000 rcf for 1 min
Materials for the application
- Ascentis® Express ES‑Cyano column, 10 cm × 3.0 mm, 2.0 µm, 51732‑U
- Acetonitrile hypergrade for LC‑MS, 100029
- Methanol hypergrade for LC‑MS, 106035
- Water for chromatography LC‑MS grade, 115333
- Acetic acid 100 percent for LC‑MS, 533001
- Ammonium formate at least 99.0 percent for LC‑MS, 70221
- Formic acid 98 to 100 percent for LC‑MS, 533002
- Zopiclone reference standards and related compounds, Z4900, Z‑003, Z3001000
How this case study fits the broader LC‑MS toolkit
This targeted UHPLC‑MS approach complements workflows highlighted for other drug classes. According to the experiment data, the Ascentis® Express ES‑Cyano column supports sensitive Z‑drug assays that align with urine testing needs. Together with options such as the Ascentis® Express C18 column, Supel™ Swift HLB 96‑well SPE plates, Astec® CHIROBIOTIC® V2, Ascentis® Express Phenyl‑Hexyl HPLC Column, Purospher™ STAR RP‑18 endcapped, and Ascentis® Express Biphenyl Column, researchers can configure fit‑for‑purpose LC‑MS methods. All featured products, including Supelco R Analytical Products, are available through Chemical Express.
Screening and confirmation integration with Supelco and Ascentis solutions
Integrated screening and confirmation
LC-MS/MS is the gold standard for confirmatory drug testing across the compound classes described. LC-TOF-MS is used for comprehensive drug screening. According to the trends highlighted, miniaturization in separation and detection enhances rapid, sensitive drugs of abuse testing. End to end workflows using Supelco R Analytical Products and Ascentis® columns support monitoring needs for opioids, designer drugs, synthetic hallucinogens, amphetamines, alcohol markers, and Z-drugs in biological samples.
Method selection and development essentials
Define analytical goals before starting the lab work. Balance method dimensions to ensure robustness. Use official methods and peer-reviewed studies as anchors and validate new methods for routine use.
- Define goals: resolution, analysis time, sensitivity.
- Balance: selectivity, speed, efficiency and price-per-analysis.
- Avoid errors: unclear goals, poor chemistry knowledge, trial and error, wrong instrument setup.
- Leverage literature, official methods, and reference materials.
- Plan verification, validation, and method transfer for routine implementation.
Biological matrices and sample preparation
Plasma, serum, tissue, and urine are common matrices. Plasma and serum are stored to −20 °C without special precautions, while urine requires preservatives. Analyte loss during pre-treatment is inevitable, so internal standards should be added at the start to monitor recovery.
- LLE is non-selective, can co-extract lipids, often uses large solvent volumes, and may require glassware.
- SPE offers better recoveries, less solvent use, smaller sample volumes, and higher throughput than LLE.
- Supel™ Swift HLB 96-well SPE plates enable high-throughput urine cleanup prior to LC-MS/MS.
According to the experiment data
- Using Supel™ Swift HLB 96-well SPE plates, 12 of 13 analytes showed 73–105 percent recovery with RSDs less than 7.2 percent.
- Overall recovery excluding buprenorphine averaged 88 percent.
- Buprenorphine recovery was lower at 44 percent, attributed to log P near 5.
- Matrix effects were minimal, within ±10 percent ionization impact after SPE cleanup.
Deploying the right stationary phase or technology
Match analyte chemistry and analytical goals to column and workflow choices drawn from the case studies.
- Ascentis® Express Biphenyl Column for fentanyl and related analogs in urine; pi pi stacking with the biphenyl phase improves resolution of structurally similar analytes.
- Purospher™ STAR RP-18 endcapped for UHPLC-MS/MS quantitation of buprenorphine or tramadol in urine with isotopically labelled internal standards.
- Ascentis® Express Phenyl-Hexyl HPLC Column for rapid LC-MS/MS panels covering 13 pain management opioids with certified reference materials.
- Ascentis® Express C18 column for NBOMe drugs after HLB SPE and for phosphatidylethanol markers.
- Ascentis® Express HILIC and SeQuant® ZIC®-HILIC for polar targets including bath salts and alcohol biomarkers EtG and EtS.
- Ascentis® Express ES-Cyano column for Z-drugs such as zopiclone and metabolites under UHPLC-MS conditions.
- Astec® CHIROBIOTIC® V2 for chiral LC-MS separations of amphetamine and methamphetamine enantiomers after SPE.
Workflow integration from sampling to confirmation
Fit for purpose workflows follow a structured path and leverage isotopically labelled internal standards for accurate quantification.
- Sampling and preservation, fortification, sample preparation, and matrix adjustments.
- Add internal standards, perform chemical analysis, and analyze data.
- Post-analytical steps include validation and method transfer protocols.
- BioSPME options, as described for fentanyl analogs, minimize protein interference and matrix effects while simplifying steps.
Implementation with Chemical Express
Monitoring of drugs of abuse is an internationally coordinated effort across the EU and US, supported by organizations such as EMCDDA and FDA. Chemical Express supplies the highlighted tools to build robust, fit for purpose methods that align with these monitoring and regulatory needs.
- Supelco R Analytical Products, Ascentis® Express Biphenyl Column, Purospher™ STAR RP-18 endcapped, Ascentis® Express Phenyl-Hexyl HPLC Column, Supel™ Swift HLB 96-well SPE plates, Ascentis® Express C18 column, Ascentis® Express ES-Cyano column, and Astec® CHIROBIOTIC® V2 are available from Chemical Express.
- These solutions enable integrated screening and confirmation across diverse drug classes and matrices.
Interested in the products or need more technical details?
We’re always happy to assist! Submit an inquiry or connect with us directly via LINE.
